Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Breast Cancer Research

Fig. 4

From: Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Fig. 4

Association between CD8 status and tamoxifen benefit. The boxplots show the distribution of CD8 scores among all ER-positive tumors (a). The proportion of patients with the tumors classified as high-CD8 based on the cut-off defined in Fig. 3 are plotted in green. Kaplan-Meier curves and adjusted hazard ratios (HRs) of CD8 status were calculated in patients who did not receive adjuvant tamoxifen (b) and who received adjuvant tamoxifen for 1 or 3 years (c). The same analysis was applied within ER-positive/HER2-negative patients (d, e, and f). Statistical differences in survival were calculated by the log-rank test (p). Multivariable models were stratified by lymph node status and included CD4, CD8, and FOXP3 status; morphology type; tumor grade; tumor size; age at diagnosis; PR; HER2 (when applicable); and PIK3CA mutation status. Abbreviation: HR hazard ratio, CI confidence interval, ER estrogen receptor, RFS relapse-free survival

Back to article page